Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate

Journal of Neuro-Oncology

Volumn 59, Issue 3, 2002, Pages 239-242

  Baker, M J ^a   Brem, S ^a,b,c   Daniels, S ^a   Sherman, B ^a   Phuphanich, S ^a,b,c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Department of Interdisciplinary Oncology   (United States)

Author keywords

Astrocytoma; Biological response modifier; Brain tumor; Differentiation agent; Glioma; Phenylbutyrate

Indexed keywords

4 PHENYLBUTYRIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARMUSTINE; CISPLATIN; GABAPENTIN; LOMUSTINE; PHENYTOIN; PROCARBAZINE; THYROID HORMONE; VINCRISTINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CASE REPORT; CONTINUOUS INFUSION; CORPUS CALLOSUM; DISEASE SEVERITY; DOSE RESPONSE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERABILITY; FEMALE; FRONTAL LOBE; FUNCTIONAL ASSESSMENT; GLIOBLASTOMA; HEADACHE; HUMAN; HYPOTHYROIDISM; LEARNING DISORDER; LONG TERM CARE; MULTIPLE CANCER; NAUSEA; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RECURRENT CANCER; SEIZURE; TEMPORAL LOBE; VERTIGO;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; LOMUSTINE; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; PHENYLBUTYRATES; PROCARBAZINE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0036712208     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1019905127442     Document Type: Article

References (15)

1. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991
2. Perspectives in the treatment of malignant gliomas in adults
3. The New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Organization, objectives, and activities
4. Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells
5. Dose escalation study of oral sodium phenylbutyrate in patients with refractory high grade astrocytomas: Maximum tolerated dose, toxicity profile, pharmacology, and survival
6. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells
7. Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate
8. Phase I study of phenylacetate administration twice daily to patients with cancer
9. Phenylacetate and phenylbutyrate as novel, non-toxic differentiation inducers
10. Phase II study of phenylacetate in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report
11. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma
12. Selective activity of phenylacetate against malignant gliomas: Resemblance to fetal brain damage in phenylketonuria
13. Induction of apoptosis in malignant B cells by phenylbutyrate or phenyl acetate in combination with chemotherapeutic agents
14. Prediction of central nervous system embryonal tumour outcome based on gene expression
15. Angiogenesis and cancer control: From concept to therapeutic trial